These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 11502441)

  • 1. Luteinizing hormone-releasing hormone antagonists in prostate cancer.
    Stricker HJ
    Urology; 2001 Aug; 58(2 Suppl 1):24-7. PubMed ID: 11502441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer.
    Tomera K; Gleason D; Gittelman M; Moseley W; Zinner N; Murdoch M; Menon M; Campion M; Garnick MB
    J Urol; 2001 May; 165(5):1585-9. PubMed ID: 11342922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
    Garnick MB; Mottet N
    BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An open-label study of abarelix in men with symptomatic prostate cancer at risk of treatment with LHRH agonists.
    Koch M; Steidle C; Brosman S; Centeno A; Gaylis F; Campion M; Garnick MB;
    Urology; 2003 Nov; 62(5):877-82. PubMed ID: 14624912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer.
    McLeod D; Zinner N; Tomera K; Gleason D; Fotheringham N; Campion M; Garnick MB;
    Urology; 2001 Nov; 58(5):756-61. PubMed ID: 11711355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancer.
    Debruyne F; Bhat G; Garnick MB
    Future Oncol; 2006 Dec; 2(6):677-96. PubMed ID: 17155895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer.
    Trachtenberg J; Gittleman M; Steidle C; Barzell W; Friedel W; Pessis D; Fotheringham N; Campion M; Garnick MB;
    J Urol; 2002 Apr; 167(4):1670-4. PubMed ID: 11912385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gonadotropin-releasing hormone: an update review of the antagonists versus agonists.
    Van Poppel H; Klotz L
    Int J Urol; 2012 Jul; 19(7):594-601. PubMed ID: 22416801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abarelix Depot, a GnRH antagonist, v LHRH superagonists in prostate cancer: differential effects on follicle-stimulating hormone. Abarelix Depot study group.
    Garnick MB; Campion M
    Mol Urol; 2000; 4(3):275-7. PubMed ID: 11062384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
    Hall MC; Fritzsch RJ; Sagalowsky AI; Ahrens A; Petty B; Roehrborn CG
    Urology; 1999 May; 53(5):898-902; discussion 902-3. PubMed ID: 10223480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting FSH in androgen-independent prostate cancer: abarelix for prostate cancer progressing after orchiectomy.
    Beer TM; Garzotto M; Eilers KM; Lemmon D; Wersinger EM
    Urology; 2004 Feb; 63(2):342-7. PubMed ID: 14972486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Luteinizing hormone-releasing hormone agonists in the treatment of men with prostate cancer: timing, alternatives, and the 1-year implant.
    Marks LS
    Urology; 2003 Dec; 62(6 Suppl 1):36-42. PubMed ID: 14706507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer.
    Kirby RS; Fitzpatrick JM; Clarke N
    BJU Int; 2009 Dec; 104(11):1580-4. PubMed ID: 20053189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters.
    Yannucci J; Manola J; Garnick MB; Bhat G; Bubley GJ
    J Urol; 2006 Aug; 176(2):520-5. PubMed ID: 16813881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A New Sustained-release, 3-Month Leuprolide Acetate Formulation Achieves and Maintains Castrate Concentrations of Testosterone in Patients With Prostate Cancer.
    Shore ND; Guerrero S; Sanahuja RM; Gambús G; Parente A
    Clin Ther; 2019 Mar; 41(3):412-425. PubMed ID: 30929678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists.
    Klotz L; Miller K; Crawford ED; Shore N; Tombal B; Karup C; Malmberg A; Persson BE
    Eur Urol; 2014 Dec; 66(6):1101-8. PubMed ID: 24440304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues.
    Weckermann D; Harzmann R
    Eur Urol; 2004 Sep; 46(3):279-83; discussion 283-4. PubMed ID: 15306097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of LHRH antagonists for advanced prostate cancer.
    Moul JW
    Can J Urol; 2014 Apr; 21(2 Supp 1):22-7. PubMed ID: 24775720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm.
    Oefelein MG; Cornum R
    J Urol; 2000 Sep; 164(3 Pt 1):726-9. PubMed ID: 10953134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients.
    Damber JE; Tammela TL; Iversen P; Abrahamsson PA; Boccon-Gibod L; Olesen TK; van der Meulen E; Persson BE
    Urology; 2012 Jul; 80(1):174-80. PubMed ID: 22748873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.